Relationship between various clinical outcome assessments in patients with blepharospasm.
Identifieur interne : 002448 ( Ncbi/Curation ); précédent : 002447; suivant : 002449Relationship between various clinical outcome assessments in patients with blepharospasm.
Auteurs : Joseph Jankovic [États-Unis] ; Christopher Kenney ; Susanne Grafe ; Roman Goertelmeyer ; George ComesSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2009.
English descriptors
- KwdEn :
- Aged, Blepharospasm (diagnosis), Blepharospasm (drug therapy), Blepharospasm (physiopathology), Botulinum Toxins, Type A (therapeutic use), Disability Evaluation, Double-Blind Method, Female, Glasgow Outcome Scale, Humans, Male, Neuromuscular Agents (therapeutic use), Prospective Studies, Questionnaires, Severity of Illness Index.
- MESH :
- chemical , therapeutic use : Botulinum Toxins, Type A, Neuromuscular Agents.
- diagnosis : Blepharospasm.
- drug therapy : Blepharospasm.
- physiopathology : Blepharospasm.
- Aged, Disability Evaluation, Double-Blind Method, Female, Glasgow Outcome Scale, Humans, Male, Prospective Studies, Questionnaires, Severity of Illness Index.
Abstract
The objective was to analyze the metric properties of the Jankovic Rating Scale (JRS) and a self-rating patient response outcome scale, the Blepharospasm Disability Index (BSDI), in blepharospasm patients. Data from a randomized, double-blind, active-control clinical trial in 300 patients with blepharospasm treated with either botulinum toxin type A (Botox) or NT201 (Xeomin) were used to evaluate the metric properties of the JRS and the BSDI compared with the Patient Evaluation of Global Response (PEGR) and Global Assessment Scale (GAS). The internal consistency of the BSDI was high, Cronbach's Alpha = 0.88, and the retest reliability of the BSDI single items was adequate, Spearman's rank coefficient = 0.453 < r < 0.595. The correlation between JRS sum score and BSDI weighted mean score was r = 0.487 (baseline) and r = 0.737 (control visit), respectively. Using the GAS and PEGR, the results suggest that a change of 2 points in the JRS and of 0.7 points in the BSDI are clinically meaningful. JRS and BSDI are objective indicators of clinical efficacy as suggested by their good validity when compared with physicians' and patients' rating scales. Both, JRS and BSDI, can be used to reliably assess blepharospasm in treatment trials.
DOI: 10.1002/mds.22368
PubMed: 19053054
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F16
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :001F16
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001B96
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002448
Links to Exploration step
pubmed:19053054Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Relationship between various clinical outcome assessments in patients with blepharospasm.</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA. josephj@bcm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030</wicri:regionArea><wicri:noRegion>Texas 77030</wicri:noRegion><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name></author><author><name sortKey="Grafe, Susanne" sort="Grafe, Susanne" uniqKey="Grafe S" first="Susanne" last="Grafe">Susanne Grafe</name></author><author><name sortKey="Goertelmeyer, Roman" sort="Goertelmeyer, Roman" uniqKey="Goertelmeyer R" first="Roman" last="Goertelmeyer">Roman Goertelmeyer</name></author><author><name sortKey="Comes, George" sort="Comes, George" uniqKey="Comes G" first="George" last="Comes">George Comes</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2009">2009</date><idno type="doi">10.1002/mds.22368</idno><idno type="RBID">pubmed:19053054</idno><idno type="pmid">19053054</idno><idno type="wicri:Area/PubMed/Corpus">001F16</idno><idno type="wicri:Area/PubMed/Curation">001F16</idno><idno type="wicri:Area/PubMed/Checkpoint">001B96</idno><idno type="wicri:Area/Ncbi/Merge">002448</idno><idno type="wicri:Area/Ncbi/Curation">002448</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Relationship between various clinical outcome assessments in patients with blepharospasm.</title><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="1"><nlm:affiliation>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030, USA. josephj@bcm.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas 77030</wicri:regionArea><wicri:noRegion>Texas 77030</wicri:noRegion><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Kenney, Christopher" sort="Kenney, Christopher" uniqKey="Kenney C" first="Christopher" last="Kenney">Christopher Kenney</name></author><author><name sortKey="Grafe, Susanne" sort="Grafe, Susanne" uniqKey="Grafe S" first="Susanne" last="Grafe">Susanne Grafe</name></author><author><name sortKey="Goertelmeyer, Roman" sort="Goertelmeyer, Roman" uniqKey="Goertelmeyer R" first="Roman" last="Goertelmeyer">Roman Goertelmeyer</name></author><author><name sortKey="Comes, George" sort="Comes, George" uniqKey="Comes G" first="George" last="Comes">George Comes</name></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2009" type="published">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Blepharospasm (diagnosis)</term><term>Blepharospasm (drug therapy)</term><term>Blepharospasm (physiopathology)</term><term>Botulinum Toxins, Type A (therapeutic use)</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Female</term><term>Glasgow Outcome Scale</term><term>Humans</term><term>Male</term><term>Neuromuscular Agents (therapeutic use)</term><term>Prospective Studies</term><term>Questionnaires</term><term>Severity of Illness Index</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Blepharospasm</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Blepharospasm</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Disability Evaluation</term><term>Double-Blind Method</term><term>Female</term><term>Glasgow Outcome Scale</term><term>Humans</term><term>Male</term><term>Prospective Studies</term><term>Questionnaires</term><term>Severity of Illness Index</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The objective was to analyze the metric properties of the Jankovic Rating Scale (JRS) and a self-rating patient response outcome scale, the Blepharospasm Disability Index (BSDI), in blepharospasm patients. Data from a randomized, double-blind, active-control clinical trial in 300 patients with blepharospasm treated with either botulinum toxin type A (Botox) or NT201 (Xeomin) were used to evaluate the metric properties of the JRS and the BSDI compared with the Patient Evaluation of Global Response (PEGR) and Global Assessment Scale (GAS). The internal consistency of the BSDI was high, Cronbach's Alpha = 0.88, and the retest reliability of the BSDI single items was adequate, Spearman's rank coefficient = 0.453 < r < 0.595. The correlation between JRS sum score and BSDI weighted mean score was r = 0.487 (baseline) and r = 0.737 (control visit), respectively. Using the GAS and PEGR, the results suggest that a change of 2 points in the JRS and of 0.7 points in the BSDI are clinically meaningful. JRS and BSDI are objective indicators of clinical efficacy as suggested by their good validity when compared with physicians' and patients' rating scales. Both, JRS and BSDI, can be used to reliably assess blepharospasm in treatment trials.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002448 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002448 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:19053054
|texte= Relationship between various clinical outcome assessments in patients with blepharospasm.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:19053054" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a MovDisordV3
| This area was generated with Dilib version V0.6.23. |  |